Skip to content

Comorbidity and vascular risk

TL;DR — Migraine co-occurs with depression, anxiety, sleep disorders, epilepsy and other pain syndromes; these relationships are often bidirectional and can amplify disability and treatment complexity without proving one shared cause. Migraine is associated with stroke in observational meta-analysis (total stroke pooled OR/RR 1.62, 95% CI 1.44–1.83), with the most reproducible signal for ischemic stroke in migraine with aura (Zhang 2022, PMID 35451664). Relative risk is not absolute risk: for many young people baseline stroke incidence is low, while smoking, estrogen exposure, hypertension and thrombosis materially change the denominator. PFO is associated with migraine in observational studies, but randomized closure trials have not established PFO closure as migraine treatment (Elbadawi 2019, PMID 29914296). A 2026 active-comparator cohort found CGRP-antibody initiation non-inferior to onabotulinumtoxinA for ischemic stroke/TIA, but only 36 events occurred and the study explicitly did not establish protection or equivalence (Gül 2026, PMID 42390441).

Comorbidity is several different claims

Claim Required evidence Common overreach
Two diagnoses co-occur Representative prevalence/odds study Assuming causality
Relationship is bidirectional Longitudinal incidence in both directions Treating temporal sequence as mechanism
Biology is shared Genetic/mechanistic convergence Equating pathway overlap with same disease
One treatment helps both Prespecified outcomes for both conditions Attributing mood improvement only to direct antidepressant action
One condition modifies prognosis Adjusted longitudinal cohort Ignoring severity and care confounding

Comorbidity changes drug selection, safety and outcomes even when mechanism is unresolved. It also inflates total disability beyond headache-day counts.

Migraine and depression/anxiety are consistently associated in adults and are also reported in pediatric review evidence (Amouroux 2008, PMID 19068340). Direction can run from repeated unpredictable disability to mood symptoms, from mood/sleep biology to attack susceptibility, or from shared genetic/environmental factors. Panic disorder has particularly strong reported comorbidity and shares episodic symptoms and interictal anticipatory anxiety (Smitherman 2013, PMID 23278473).

Clinical issue Why it matters
Depression Disability, adherence, sleep and suicide-risk assessment
Anxiety/panic Attack fear, emergency use and symptom amplification
Bipolar spectrum Antidepressant selection and mood destabilization
Substance use Opioid/barbiturate exposure and MOH treatment
Trauma/stress disorder Sleep/arousal and behavioural-care needs

A systematic review/meta-analysis found migraine associated with suicidal ideation even across studies adjusting variably for depression; heterogeneity and observational design prevent a migraine-specific causal estimate (Friedman 2017, PMID 27648590). Suicide-risk signals require direct assessment and appropriate care, not attribution to “just migraine.”

OnabotulinumtoxinA studies report improvement in both migraine and depressive symptoms, but meta-analysis cannot cleanly separate direct mood effects from relief of chronic pain/disability and expectancy (Affatato 2021, PMID 33789668). Clinic data likewise associate mood disorders with greater migraine disability without establishing direction (Rammohan 2019, PMID 30765967). Treating migraine is not a replacement for evidence-based mood care.

Pediatric meta-analysis also finds more psychopathology symptoms in migraine than healthy controls, with smaller distinctions from tension-type headache; referral and parent-report methods matter (Balottin 2013, PMID 23203505).

Sleep

Poor sleep can precipitate attacks, attacks disrupt sleep, and depression/anxiety affect both. In CaMEO, chronic migraine was associated with worse sleep quality and higher questionnaire-defined sleep-apnoea risk than episodic migraine; the cross-sectional design cannot determine direction (Buse 2019, PMID 30381821).

Psychological sleep interventions have been tested for migraine/tension-type headache; systematic review found promising signals but few heterogeneous studies (Sullivan 2019, PMID 31015531).

Sleep presentation Distinct question
Insomnia Behavioural sleep treatment and mood/arousal
Snoring/apnoea risk Objective sleep evaluation when indicated
Restless legs Iron/medication and sleep-fragmentation assessment
Circadian irregularity Schedule stabilization
Hypersomnolence Medication effect, sleep disorder or comorbidity

“Sleep hygiene” should not substitute for diagnosing obstructive sleep apnoea or another sleep disorder.

Epilepsy

Migraine and epilepsy share episodicity, aura-like symptoms, neuronal excitability and some ion-channel genes. A population-based systematic review/meta-analysis found increased lifetime prevalence of migraine in people with epilepsy and of epilepsy in people with migraine, but study heterogeneity was substantial (Keezer 2015, PMID 25495495).

Feature Migraine aura Focal seizure
Evolution Often gradual over minutes Often sudden over seconds
Duration Usually 5–60 min per symptom Commonly seconds to a few minutes
Stereotypy Can vary attack to attack Often highly stereotyped
Visual content Spreading scotoma/fortification common Brief coloured/circular hallucinations can occur
After-event Headache/postdrome Postictal confusion, weakness or headache

Postictal headache and cognitive/behavioural symptoms are common enough to complicate retrospective classification (Subota 2019, PMID 30978637). EEG is not a routine migraine test; it is used when the event history raises seizure probability.

Some antiseizure drugs treat both conditions, but dual indication is drug-specific: topiramate/valproate have migraine evidence, while many epilepsy drugs do not. Reproductive and cognitive harms remain decisive.

Other pain and sensory syndromes

Migraine overlaps fibromyalgia, temporomandibular disorder, neck pain and functional gastrointestinal disorders. Shared sensitization, sleep/mood burden, care-seeking and ascertainment can all raise co-diagnosis. A fibromyalgia comorbidity review documents high psychiatric and chronic-pain overlap but clinic heterogeneity prevents a single transportable prevalence (Kleykamp 2021, PMID 33383293).

Comorbidity can make a treatment look ineffective if the outcome is global pain/function rather than migraine days. Conversely, improvement in one condition can reduce total symptom burden without changing the other’s core biology.

Stroke: magnitude and phenotype

Synthesis Exposure/outcome Estimate
Zhang 2022 Any migraine → total stroke OR/RR 1.62 (95% CI 1.44–1.83) (PMID 35451664)
Schürks 2009 Migraine, especially aura → ischemic stroke Association strongest in women, younger age, smoking/oral contraception strata (PMID 19861375)
Ng 2022 Prospective cohorts → MI, stroke, CV mortality Stroke/MI signals varied; CV mortality less consistent (PMID 34997286)
Sacco 2015 Migraine → ischemic heart disease Heterogeneous observational evidence (PMID 25808832)
Schürks 2011 Migraine → mortality No consistent all-cause mortality increase; aura-stratified data sparse (PMID 21803936)

Meta-analysis combines case-control and cohort definitions, self-report and clinician diagnosis, and variable adjustment. A pooled ratio is therefore an association across study architectures, not an individualized forecast.

Four migraine–stroke relationships

  1. Shared susceptibility: genetics, endothelial function, thrombosis or exposures affect both.
  2. Stroke with migraine-like symptoms: ischemia can cause headache and positive/spreading deficits.
  3. Migrainous infarction: an aura persists >60 minutes and imaging shows infarction in the relevant territory; rare.
  4. Treatment/exposure interaction: smoking, estrogen, vasoconstrictive drugs or risk-factor management changes absolute risk.

Reviews emphasize endothelial dysfunction, cortical spreading depolarization, PFO/embolism and hypercoagulability as candidates, with no single complete mechanism. Genetic-risk concordance across migraine subgroups supports substantial shared susceptibility rather than wholly distinct aura and non-aura diseases (Magalhães 2018, PMID 30117565; Tietjen 2018, PMID 28181217; Nyholt 2015, PMID 25179292).

Absolute versus relative risk

If baseline annual stroke risk is 2 per 100,000, a doubled relative risk would be 4 per 100,000—an excess of 2. If baseline risk is 200 per 100,000, the same ratio implies an excess of 200. These are illustrative calculations, not migraine-specific estimates. Age, blood pressure, smoking, diabetes, thrombosis, pregnancy/postpartum and estrogen exposure set the baseline.

This is why “aura doubles stroke risk” is incomplete without population, age, sex and exposures. Risk communication should show both denominator and uncertainty.

Patent foramen ovale

PFO occurs in roughly 20–34% of adults and is usually benign (Giblett 2019, PMID 30858890). Observational association with migraine—especially aura—prompted closure trials, but association may reflect selection, shared genetics or embolic biology.

Evidence Result
Uncontrolled closure series Often reported migraine improvement; high selection/placebo risk
Randomized migraine trials Primary endpoints generally negative; secondary/subgroup signals inconsistent
Meta-analysis of 3 RCTs/484 participants No robust basis for routine closure as migraine therapy (Elbadawi 2019, PMID 29914296)
Stroke-prevention closure Separate indication in selected cryptogenic-stroke patients; cannot be generalized to migraine

Reviews conclude there is insufficient evidence for a causal PFO–migraine link and that closure should not be undertaken solely to treat migraine (Diener 2007, PMID 17504652; Tariq 2016, PMID 26952049; Hildick-Smith 2017, PMID 28886844).

Cardiovascular disease and mortality

Prospective-cohort meta-analysis reports modest associations between migraine and myocardial infarction/stroke, stronger for aura in many studies (Ng 2022, PMID 34997286). Ischemic-heart-disease meta-analysis found inconsistent subtype and sex effects (Sacco 2015, PMID 25808832). Mortality meta-analysis did not establish a consistent overall excess, showing why nonfatal vascular association and death must not be conflated (Schürks 2011, PMID 21803936).

Treatment implications

Comorbidity Potential alignment Main caution
Depression/anxiety CBT; some antidepressant preventive choices Bipolarity, overdose risk, interactions
Epilepsy Topiramate/valproate may address both Cognitive/reproductive harms; not all antiseizure drugs work for migraine
Hypertension Candesartan/beta-blocker alignment Hypotension, asthma, pregnancy
Vascular disease Non-vasoconstrictive acute options Trial exclusions still limit direct high-risk evidence
Insomnia CBT-I; selected sedating preventive Daytime sedation and anticholinergic load

The 2026 All of Us active-comparator analysis observed 14 ischemic-stroke/TIA events among 1,581 CGRP-antibody initiators and 22 among 947 onabotulinumtoxinA initiators (adjusted HR 0.524, 95% CI 0.263–1.046). It met a prespecified non-inferiority margin but was imprecise, lacked a feasible untreated comparison and cannot be read as a protective effect (Gül 2026, PMID 42390441). As of the 2026-08-30 search, migraine-prevention studies therefore inform comparative safety more than whether suppressing migraine lowers vascular-event incidence. Vascular risk modification follows standard evidence for smoking cessation, blood pressure, lipids, diabetes and appropriate contraception—not a substitute migraine endpoint.

Open questions

  • How much of migraine–stroke association is causal versus shared genetics/exposure and ascertainment? (Zhang 2022, PMID 35451664)
  • Does reducing aura frequency alter vascular events independently of established risk factors? (Magalhães 2018, PMID 30117565)
  • Which comorbidity clusters predict chronification or treatment response rather than simply greater baseline burden? (Buse 2019, PMID 30381821)
  • Can joint migraine–mood trials separate direct psychiatric effect from disability-mediated improvement? (Affatato 2021, PMID 33789668)
  • What biological feature explains epilepsy–migraine co-occurrence in the majority without monogenic channelopathy? (Keezer 2015, PMID 25495495)

References

  1. Zhang S, et al. Association between migraine and risk of stroke: systematic review and meta-analysis. Neurol Sci. 2022. PMID 35451664
  2. Schürks M, et al. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ. 2009. PMID 19861375
  3. Ng CY, et al. Myocardial infarction, stroke and cardiovascular mortality among migraine patients. J Neurol. 2022. PMID 34997286
  4. Sacco S, et al. Migraine and risk of ischaemic heart disease: systematic review and meta-analysis. Eur J Neurol. 2015. PMID 25808832
  5. Schürks M, et al. Migraine and mortality: systematic review and meta-analysis. Cephalalgia. 2011. PMID 21803936
  6. Magalhães JE, et al. Migraine and cerebrovascular diseases: epidemiology and clinical considerations. Headache. 2018. PMID 30117565
  7. Tietjen GE, et al. Hypercoagulability and migraine. Headache. 2018. PMID 28181217
  8. Smitherman TA, et al. Panic disorder and migraine: comorbidity and implications. Headache. 2013. PMID 23278473
  9. Friedman LE, et al. Migraine and suicidal ideation: systematic review and meta-analysis. Clin J Pain. 2017. PMID 27648590
  10. Affatato O, et al. OnabotulinumtoxinA in comorbid migraine and depression: meta-analysis. J Transl Med. 2021. PMID 33789668
  11. Balottin U, et al. Psychopathological symptoms in child/adolescent migraine: meta-analysis. Cephalalgia. 2013. PMID 23203505
  12. Buse DC, et al. Sleep disorders among people with migraine: CaMEO. Headache. 2019. PMID 30381821
  13. Sullivan DP, et al. Psychological sleep interventions for migraine and tension-type headache. Sci Rep. 2019. PMID 31015531
  14. Keezer MR, et al. Comorbid relationship between migraine and epilepsy: systematic review and meta-analysis. Eur J Neurol. 2015. PMID 25495495
  15. Subota A, et al. Postictal signs and symptoms in epilepsy: systematic review and meta-analysis. Epilepsy Behav. 2019. PMID 30978637
  16. Kleykamp BA, et al. Psychiatric and chronic-pain comorbidities in fibromyalgia. Semin Arthritis Rheum. 2021. PMID 33383293
  17. Elbadawi A, et al. Randomized trials of PFO closure for migraine: meta-analysis. Acta Cardiol. 2019. PMID 29914296
  18. Giblett JP, et al. Patent foramen ovale closure in 2019. Interv Cardiol. 2019. PMID 30858890
  19. Hildick-Smith D, Williams TM. Patent foramen ovale and migraine headache. Interv Cardiol Clin. 2017. PMID 28886844
  20. Diener HC, et al. Patent foramen ovale and migraine. Curr Pain Headache Rep. 2007. PMID 17504652
  21. Tariq N, et al. Patent foramen ovale and migraine: closing the debate. Headache. 2016. PMID 26952049
  22. Nyholt DR, et al. Concordance of genetic risk across migraine subgroups. Cephalalgia. 2015. PMID 25179292
  23. Rammohan K, et al. Migraine and mood disorders: prevalence, correlations and disability. J Neurosci Rural Pract. 2019. PMID 30765967
  24. Amouroux R, et al. Anxiety and depression in children and adolescents with migraine. Encephale. 2008. PMID 19068340
  25. Gül M, et al. Cerebrovascular risk with CGRP monoclonal antibodies versus onabotulinumtoxinA in patients with migraine. Cephalalgia. 2026. PMID 42390441